{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:ema.taxotere:0 retrieved successfully",
    "request_url": "http://api.moalmanac.org/indications?indication_id=ind%3Aema.taxotere%3A0",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.006017,
    "timestamp_received": "2026-04-24T17:04:02.210538+00:00Z",
    "timestamp_returned": "2026-04-24T17:04:02.216555+00:00Z",
    "trace_id": "14d4f350-981e-43dc-a4fc-e6cd170f7bfe"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-04-09"
  },
  "data": [
    {
      "id": "ind:ema.taxotere:0",
      "indication": "TAXOTERE in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express HER2 and who previously have not received chemotherapy for metastatic disease.",
      "initial_approval_date": "2005-12-22",
      "initial_approval_url": "https://www.ema.europa.eu/en/documents/scientific-discussion/taxotere-epar-scientific-discussion_en.pdf",
      "description": "The European Medicines Agency (EMA) has authorized docetaxel in combination with trastuzumab for the treatment of patients with metastatic breast cancer whose tumors over express HER2 and who previously have not received chemotherapy for metastatic disease.",
      "raw_biomarkers": "HER2 overexpression",
      "raw_cancer_type": "breast cancer",
      "raw_therapeutics": "Taxotere (docetaxel)",
      "icd10": null,
      "regimen_code": null,
      "reimbursement_category": null,
      "reimbursement_date": null,
      "reimbursement_details": null,
      "date_regular_approval": null,
      "date_accelerated_approval": null,
      "document": {
        "id": "doc:ema.taxotere",
        "type": "Document",
        "documentType": "Regulatory approval",
        "name": "Taxotere (docetaxel) [product information]. EMA.",
        "title": null,
        "aliases": [],
        "description": "Sanofi Winthrop Industrie. Taxotere (docetaxel) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/taxotere-epar-product-information_en.pdf. Revised December 2023. Accessed March 11, 2024.",
        "urls": [
          "https://www.ema.europa.eu/en/medicines/human/EPAR/taxotere",
          "https://www.ema.europa.eu/en/documents/product-information/taxotere-epar-product-information_en.pdf"
        ],
        "doi": null,
        "pmid": null,
        "extensions": [
          {
            "name": "agent",
            "value": {
              "id": "ema",
              "type": "Agent",
              "agentType": "organization",
              "name": "European Medicines Agency",
              "description": "Regulatory agency that approves medicines for use in the European Union.",
              "extensions": [
                {
                  "name": "last_updated",
                  "value": "2025-10-01",
                  "description": ""
                },
                {
                  "name": "url",
                  "value": "https://www.ema.europa.eu/en/medicines",
                  "description": ""
                }
              ]
            },
            "description": "The organization that published this document."
          },
          {
            "name": "company",
            "value": "Sanofi Winthrop Industrie.",
            "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_brand",
            "value": "Taxotere",
            "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_generic",
            "value": "docetaxel",
            "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "first_publication_date",
            "value": "2009-01-13",
            "description": "The publication date for the initial version of this document."
          },
          {
            "name": "identification_number",
            "value": null,
            "description": "Identification number used by the publishing organization."
          },
          {
            "name": "publication_date",
            "value": "2023-12-14",
            "description": "The publication date for the document."
          },
          {
            "name": "status",
            "value": "Active",
            "description": "Whether this document is Active or Deprecated within moalmanac-db."
          }
        ]
      }
    }
  ]
}